Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTS105 in advanced hepatocellular carcinoma
NCT06689540Phase 1Recruiting
- Start
- Nov 2024
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, Lipid-based Nanoparticles, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of MTS105 in hepatocellular carcinoma (HCC) (6 arms). Primary endpoints: Treatment-emergent adverse events at 4 weeks and Maximal Tolerance Dose at 28 days. Started Nov 2024; status: recruiting.
02
Drugs
MTS105
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06689540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06689540.